# Thymosin Alpha-1: A Research Digest of the Thymic Immunomodulator

> Thymosin Alpha-1 is a 28-amino-acid thymic immunomodulatory peptide studied for immune reconstitution across four decades of trials. A cited, evidence-graded literature digest.

A plain-English, evidence-graded digest of what the published literature actually measured — strongest in chronic viral hepatitis, null in the largest sepsis trial, mixed in COVID-19, exploratory in HIV — with every figure cited.

## The short version

Thymosin Alpha-1 is a small protein your own body makes. It is 28 amino acids long — a short chain of the building blocks that make up all proteins — and it is one of several "thymic" peptides, meaning peptides linked to the thymus, the small gland behind the breastbone that trains immune cells. Its job is to nudge the immune system: it helps certain cells mature and talk to each other so the body can mount a better defense, while also keeping that defense from running too hot. Researchers have studied it for chronic hepatitis B, for sepsis, for COVID-19, for cancer support, and for rebuilding immunity in people with HIV. The honest summary is that the evidence is real but uneven — clearest in chronic viral hepatitis, and weakest in sepsis, where the largest careful trial found no benefit. The synthetic drug version is called thymalfasin, and it is approved in roughly 35 countries — but not in the United States. What people report, including the downsides, is on [the effects page](/effects).

## What the Thymosin Alpha-1 literature has actually measured

Thymosin Alpha-1 (Tα1; the synthetic drug carries the generic name thymalfasin) is a 28-amino-acid, N-terminally acetylated peptide cleaved in the body from a larger precursor called prothymosin alpha. Allan Goldstein and colleagues first isolated it from calf thymus and, in 1977, determined its complete amino-acid sequence [1]. It is an *immunomodulator* — a molecule that adjusts immune activity — not a growth or muscle-building peptide.

Its mechanism is well characterized. Tα1 signals through Toll-like receptors (TLR2 and TLR9 — sensors on immune cells that detect danger) on dendritic cells (the immune system's antigen-presenting "scouts"), pushing them to mature and prime T-cells toward a Th1, cell-mediated response. In parallel it activates an enzyme called indoleamine 2,3-dioxygenase (IDO), which generates a regulatory, calming arm — so the same peptide can restore effector immunity in an immunosuppressed person while damping over-inflammation [5].

The four-decade trial record is graded, not uniform. In chronic hepatitis B, adding Tα1 to lamivudine raised hepatitis B e-antigen seroconversion to 45.1% versus 15.2% for lamivudine alone across a meta-analysis of eight trials [13]. In sepsis the picture is the opposite: the marginally positive ETASS trial (26.0% vs 35.0% 28-day mortality) [2] was followed by the large, rigorous phase-3 TESTS trial, which was null — hazard ratio 0.99, P=0.93 [3]. This digest keeps that gradient visible on every page.

## A distinction worth getting right

Thymosin Alpha-1 is constantly confused with other "thymosin" molecules, and they are genuinely different compounds. Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide cleaved from prothymosin alpha. It is **not** the same as thymosin beta-4 (the 43-amino-acid actin-binding peptide marketed in research circles as TB-500 — and the one on the WADA Prohibited List), nor thymulin / FTS (a zinc-dependent nonapeptide), nor thymopentin / TP-5 (a pentapeptide), nor thymalin (a separate bovine thymic-extract preparation), nor prothymosin alpha (its own larger precursor). Different sequence, different size, different mechanism, different use. The [thymosin alpha 1 peptide](/what-is-thymosin-alpha-1) page lays the comparison out side by side, and the [thymosin alpha 1 benefits](/benefits) page covers what the studies report it can and cannot do.

## Where the evidence is strongest — and where it is not

The most consistent signal is in chronic viral hepatitis, where multiple randomized trials and meta-analyses report higher virological and seroconversion responses when Tα1 is combined with antivirals [12][13]. As an immune-restorative adjunct — after stem-cell transplant [9], alongside vaccines in immunosuppressed patients [11], and in HIV immune reconstitution [8] — there are real but smaller and often non-blinded studies. In sepsis, the largest and most rigorous evidence (the 2025 phase-3 TESTS trial, BMJ) is null [3]. In COVID-19, retrospective cohorts reported lower mortality [6] but a later systematic review found no statistically significant overall mortality benefit. Regulatory status anchors all of it: Thymosin Alpha-1 is not FDA-approved for marketing in the United States; the synthetic peptide thymalfasin is approved in roughly 35 other countries, and in the US the compound exists only in investigational and compounding contexts [4]. The full [Thymosin Alpha-1 research](/research) page details each setting, and the [Thymosin Alpha-1 references](/references) page lists every source.

---

A titration reading of the Thymosin Alpha-1 (thymalfasin) record — the thymic immunomodulator's strongest hepatitis-B signal logged first, the null phase-3 sepsis trial and the US non-approval held in plain sight, and the molecule kept ruled apart from thymosin beta-4, thymulin, and thymopentin; no clinic behind the rail and nothing here dosed, dispensed, or sold.